Carterra

𝗔𝗜 + 𝗛𝗧-𝗦𝗣𝗥 = 𝗔 𝗡𝗲𝘄 𝗘𝗿𝗮 𝗼𝗳 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆!   Carterra is thrilled to partner with innovators at the forefront of drug discovery. 𝗢𝗻𝗲 𝗵𝗼𝘁 𝘁𝗼𝗽𝗶𝗰: 𝗵𝗼𝘄 𝗔𝗜 𝗶𝘀 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝗲𝗮𝗿𝗰𝗵 𝗳𝗼𝗿 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱, 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝗱𝗿𝘂𝗴 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀— 𝗮𝗻𝗱 𝗔𝗯𝘀𝗰𝗶 𝗶𝘀 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗰𝗵𝗮𝗿𝗴𝗲.   ✨ Check out the latest feature in the International Biopharmaceutical Industry's Autumn 2024 issue to see how Carterra’s HT-SPR technology is helping Absci validate AI models and accelerate high-throughput lead optimization.   https://lnkd.in/d5s_wxhN   #DrugDiscovery #AI #Biotech #Innovation #HTSPR #LSA #Absci

Tony Giannetti, PhD, Associate Director of Applications, was on-site at SLAS 2025 to present the power of Carterra's newest high-throughput SPR platform.   The newly launched Carterra Ultra™ is setting new standards in high-throughput SPR screening. In collaboration with Carna Biosciences, Inc., we profiled 𝟭𝟮𝟱 𝗸𝗶𝗻𝗮𝘀𝗲𝘀 𝘄𝗶𝘁𝗵 𝟭,𝟬𝟬𝟬 𝗳𝗿𝗮𝗴𝗺𝗲𝗻𝘁𝘀, capturing 𝟭𝟮𝟱,𝟬𝟬𝟬 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗷𝘂𝘀𝘁 𝘁𝗵𝗿𝗲𝗲 𝗱𝗮𝘆𝘀. In a separate collaboration, we screened 𝟯,𝟱𝟬𝟬 𝗰𝗼𝗺𝗽𝗼𝘂𝗻𝗱𝘀 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝟵𝟮 𝗽𝗿𝗼𝘁𝗲𝗶𝗻𝘀, yielding 𝟯𝟱𝟬,𝟬𝟬𝟬 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀—one of the largest SPR experiments ever!   With enhanced sensitivity, stability, and scalability, Ultra is transforming kinase profiling and drug discovery.   https://lnkd.in/dB9CX6ns   #smallmolecule #fragmentscreening #largemolecule #SPR #HTSPR #kinases #labelfree #drugdiscovery

The Carterra team had a great time at SLAS 2025, where Ultra made its event debut. It was a great opportunity to share the latest updates and insights. Check out our Chief Commercial Officer, Tim Germann, as he discusses Carterra’s progress in 2024 and what’s ahead for 2025 in his interview with Rizwan Chaudhrey. https://lnkd.in/gv8SZYVF #SLAS2025 #CarterraUltra #smallmolecule #largemolecule

Come see Tony Giannetti, PhD, at SLAS 2025!  He’ll be explaining how SPR-based direct-binding assays enable high-throughput screening of compound-protein interactions—selectivity, specificity, and ligandability—in order to accelerate drug discovery.   More information can be found here: https://lnkd.in/dgRJZ_mQ.   Visit Carterra scientists at 𝗕𝗼𝗼𝘁𝗵 𝟮𝟮𝟱𝟮 and also stop by two posters showcasing HT-SPR technology and Carterra platforms in 𝗞𝗶𝗻𝗮𝘀𝗲 𝗮𝘀𝘀𝗮𝘆 screening and 𝗗𝗘𝗟𝘀.    #drugdiscovery #SPR #highthroughput #SLAS2025 #fbld #screening #smallmolecule #fragmentscreening

📢 Publication Alert!   How do we measure immunity against COVID-19?   Using the Carterra LSA®, researchers in this study were able to precisely measure the immune response and antibody binding in plasma from both COVID-19 survivors and vaccinated individuals. These findings offer critical insights into immunity, vaccine efficacy, and vaccine development. Congratulations to Carterra’s Ira Seferovich for being a co-author on this publication.   Check out the full paper here: https://lnkd.in/dYWzXcqM                 #antibodies #COVID19 #LSA #Carterra #PLOS #vaccine #immunity #infectiousdisease #vaccination

Introducing 𝗔𝗜𝗻𝘁𝗶𝗯𝗼𝗱𝘆—an 𝘪𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 antibody discovery challenge validated through cutting-edge experiments. This year's challenges focus on NGS datasets from Specifica, an IQVIA business targeting the SARS-CoV-2 RBD, offering an exciting opportunity to test your skills.   Antibody affinities will be expertly measured using Carterra’s LSA-XT SPR platform, ensuring high-precision and high-throughput analysis.   Learn more about the challenge here: https://lnkd.in/g2p3WWUP   #AntibodyDiscovery #Carterra #Specifica #SPR #AI #LSAXT

Don’t go to PepTalk this year and miss Dr. M Frank Erasmus explain how Specifica, an IQVIA business’s advanced antibody libraries (VHH, Fab, and scFv) deliver drug-like leads straight out of selection. Using the Carterra LSA®, they characterized these antibodies for developability, including stability, specificity, and low aggregation—matching or surpassing clinically approved benchmarks.   Read the full abstract here: https://lnkd.in/gddhqh54   #antibodies #SPR #drugdiscovery #antibodydiscovery #Carterra #Specifica

Absci just received $20M from AMD to drive their AI drug discovery engine fueled in great measure by Carterra’s HT-SPR technology.   Join Absci’s Amir S. at BioLogic Summit 2025 as he explains how SPR screening using the Carterra LSA® biosensor platforms plays a key role in identifying top-performing binders and driving therapeutic breakthroughs.   Then stop by 𝗕𝗼𝗼𝘁𝗵 𝟭𝟭𝟯 to learn more about Carterra’s high-definition HT-SPR technology.  And two scientific posters to boot—we’ll see you there!   #SPR #AntibodyDesign #drugdiscovery #kinetics #epitope #highthroughput #BioLogicSummit #ai #antibodydiscovery

📢 Publication Alert!   Scientists from Specifica, an IQVIA business, Sanofi, and others have unveiled a powerful new workflow that combines phage and yeast display, revolutionizing the search for high-affinity therapeutic antibodies.   This cutting-edge approach is faster and more efficient than traditional methods, tackling even the most challenging targets. Leveraging Carterra’s LSA® platform, researchers discovered real-time insights into how effectively these antibodies bind to their targets, ensuring stability and precision. Together, this innovation paves the way for the next generation of life-saving therapies.   Read the full article here: https://lnkd.in/dRGwRNZk   #kinases #Carterra #Specifica #Sanofi #antibodies #antibodydiscovery #drugdiscovery #therapeutics

We're thrilled to announce the shipment of our first 𝗖𝗮𝗿𝘁𝗲𝗿𝗿𝗮 𝗨𝗹𝘁𝗿𝗮™️ biosensor platform—marking a major milestone in our mission to enable faster, more efficient drug discovery. 🚀   Unveiled in September 2024, Ultra sets a new standard with its ability to handle both small and large molecules, gold-standard SPR detection, and high-throughput analysis—all while requiring minimal sample.   Discover how Carterra is shaping the future of drug discovery: https://lnkd.in/dc9hVgKf   #DrugDiscovery #Carterra #Ultra #Biotech #SPR #HighThroughput #smallmolecule #largemolecule #newtechnology